

Confirmation No. 2382

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. GMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Sheet

1

of

Application Number	10/734,917
Filing Date	December 12, 2003
First Named Inventor	David James Dooley, et al.
Art Unit	1621
Examiner Name	Deborah D. Carr
Attorney Docket Number	PC25870A

U. S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (If known)		
		US- 5,670,539	09-23-1997	Mary Ann Richardson
		US- 5,919,823	07-06-1999	Mary Ann Richardson
		US- 6,117,908	09-12-2000	Paul L. R. Andrews, et al.
		US- 6,127,418	10-03-2000	Lionel Bueno, et al.
		US- 6,248,363 B1	06-19-2001	Maheesh V. Patel, et al.
		US- 6,309,663 B1	10-30-2001	Maheesh V. Patel, et al.
		US- 6,310,098 B1	10-30-2001	Thomas J. Gutuso, Jr.
		US- 6,372,792 B1	04-16-2002	Guy Chouinard
		US- 2002-0035057 A1	03-21-2002	Virginia Pact Richter, et al.
		US- 2002-0037926 A1	03-28-2002	Nancy C. Lan
		US- 2002/0072538 A1	06-13-2002	Bertrand L. Chenard, et al.
		US- 2002/0099013 A1	07-25-2002	Thomas Piccaricello, et al.
		US- 2002/0099092 A1	07-25-2002	David Clive Blakemore, et al.
		US- 2002/0165246 A1	11-07-2002	Andrew Holman
		US- 2003/0144214 A1	07-31-2003	David Clive Blakemore, et al.
		US-		

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		WO 01/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical Inc.
		WO 01/45714 A2	06-28-2001	Glaxo Group Limited
		WO 02/34237 A1	05-02-2002	New River Pharmaceuticals Inc.
		WO 03/061656 A1	07-31-2003	Endo Pharmaceuticals Inc.
		DE 198 02 327 A1	07-29-1999	Godecke AG

Examiner Signature	<i>CD</i>	Date Considered	7/8/06
--------------------	-----------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See MPEP Chapter 13 for USPTO Patent Documents at www.uspto.gov or MPEP 601.04. *Enter Office that issued the document by the two-letter code (WIPO Standard ST.2). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

USN 10734,917
Docket No. PC25870A
Express Mail No. E515392623US
FILED December 12, 2003

RECEIVED
CENTRAL FAX CENTER

SEP 20 2005

PTO/SB/08A (04-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1648370

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Что на рынке готово для продажи

Sheet 1 of 2

Complete II Known

Application Number	10/734,917
Filing Date	12/12/2003
First Named Inventor	David J. Dooley
Art Unit	1621
Examiner Name	Unknown
Attorney Docket Number	BC25870A

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T#
		Country Code* Number* Kind Code* (# known)				
G	EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		
	WO	98/17627 A1	04-30-1998	J. S. Bryans, et al.		
	WO	99/21824 A1	05-08-1999	J. S. Bryans, et al.		
	WO	00/76958 A2	12-21-2000	T. R. Bellotti, et al.		
	WO	01/28978 A1	04-26-2001	J. S. Bryans, et al.		
	WO	01/90052 A1	11-29-2001	J. S. Bryans, et al.		

Examiner Signature Ced Date Considered 2/24

EXAMINER: Initial if references considered, whether or not citation is in conformance with WIPO ST. 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Code of IUPAC Patent Documents at www.wipo.int or WIPO ST.104. Enter Kind Code that identifies the document, by its two-letter code (WIPO Standard ST.1). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 18 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.89. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box +

PTO/SB/068 (08-07)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/734,917		
(use as many sheets as necessary)		Filing Date	December 12, 2003		
Sheet	2	of	2	First Named Inventor	David J. Dooley
				Group Art Unit	1621
				Examiner Name	Unknown
				Attorney Docket Number	PC25870A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
J		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol. 9, No. 10			T*
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290			
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199			
		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome" Current opinions in Rheumatology 2001;13:117-127			
		B. L. EHRENBURG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp.A278-A279, Vol. 48			
		E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12			
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8			
		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and ecg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2			
		I. SELAM, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Land, GB 2001:828-834; Vol. 2, No. 6			
		F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72			
		M. B. YUNUS, "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217			

Examiner Signature	<i>Cel</i>	Date Considered	<i>7/08</i>
--------------------	------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. This will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Please type a plus sign (+) inside this box.

PTO/SB/088 (08-06)

Approved for use through 10/31/2002. OMB 0851-0031
U. S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
A collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/734,917
(use as many sheets as necessary)		Filing Date	December 12, 2003
		First Named Inventor	David J. Dooley
		Group Art Unit	1621
		Examiner Name	Unknown
Sheet	1	of	1
		Attorney Docket Number	PC25870A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cto No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
G~		D. Garcia-Barreguero et al., "Treatment of restless legs syndrome with gabapentin--A double-blind, cross-over study" Neurology 2002;59:1573-1579

Examiner Signature	Cel	Date Considered	8/84
-----------------------	-----	--------------------	------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

ANN ARBOR RECEIVED 73
CENTRAL FAX CENTER

Confirmation No. 2382

PTO/SB/08A (08-07)

Approved for use through 07/31/2008. OMB 0851-0031

Customer No. 28880

SEP 20 2005

Substance for form 144B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ENTERTAINMENT WEEKLY 10

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/734,917
		Filing Date	December 12, 2003
		First Named Inventor	David James Doolcy
		Art Unit	1621
		Examiner Name	Deborah D. Carr
		Attorney Docket Number	PC 23870A
Sheet	1	of	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kindia Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of documents by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need further assistance, call 1-800-PTO-9199 (1-800-786-9199) and ask for option 2.